Acrivon Therapeutics, Inc.
ACRV
$1.39
$0.075.30%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
8/18/2025
-
TipRanks Financial Blog
Wealthedge Investment Advisors LLC Raises Stock Position in Acrivon Therapeutics, Inc. (NASDAQ:ACRV)
8/16/2025
-
Ticker Report
8/15/2025
-
TipRanks Financial Blog
8/15/2025
-
Simply Wall St
8/14/2025
-
GuruFocus
8/14/2025
-
The Fly
8/14/2025
-
TipRanks Financial Blog
8/13/2025
-
Fool.com Headlines
8/13/2025
-
GuruFocus
8/13/2025
-
GuruFocus
8/13/2025
-
TipRanks Financial Blog
8/13/2025
-
The Fly
8/13/2025
-
Globe Newswire
8/13/2025
-
Ticker Report
6/26/2025
-
Ticker Report
6/13/2025
-
TipRanks Financial Blog
5/17/2025
-
Yahoo! Finance: News
5/16/2025
-
GuruFocus
5/16/2025
-
GuruFocus
5/16/2025
-
TipRanks Financial Blog
5/16/2025
-
The Fly
5/16/2025
-
TipRanks Financial Blog
5/15/2025
-
GuruFocus
5/15/2025
-
SeekingAlpha.com: All News
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Wednesday, August 13, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 10 and 14 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
617 207 8979
Address
480 Arsenal Way
Watertown, MA 02472
Watertown, MA 02472
Country
Year Founded
Business Description
Sector
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine...
more